Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 10, 2022ObesityOpen Access

Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics

View Full Paper
Ask AI
Bookmark
Share

Authors

ILIldiko LingvayThe University of Texas Southwestern Medical CenterKBKirstine Brown‐FrandsenNovo Nordisk (Denmark)HCHelen M. ColhounPreventive Cardiology

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Lingvay et al. (2022) studied this question.

synapsesocial.com/papers/6a7e3e56567bd3ec6fb7afdchttps://doi.org/10.1002/oby.23621
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure2020 · 127 citations
  2. 2Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes2013 · 2,942 citations
  3. 3Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity2021 · 1,104 citations
  4. 4Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects2010 · 947 citations
  5. 5Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes2022 · 940 citations